ISRG Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

2.72B

+12.86%

2.249

+1.76%

2.61B

+15.95%

2.122

+17.23%

2.78B

+14.14%

2.424

+10.68%

Estimates Revision

The market is revising Upward the revenue expectations for Intuitive Surgical, Inc. (ISRG) for FY2025, with the revenue forecasts being adjusted by 1.35% over the past three months. During the same period, the stock price has changed by 31.72%.

Revenue Estimates for FY2025

Revise Upward

+1.35%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+5.87%

In Past 3 Month

Stock Price

Go Up

+31.72%

In Past 3 Month

20 Analyst Rating

Wall Street analysts forecast ISRG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ISRG is 612.47 USD with a low forecast of 440.00 USD and a high forecast of 700.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Buy

3 Hold

1 Sell

Strong Buy

Current: 0.000

Low

440.00

Averages

612.47

High

700.00

Current: 0.000

Low

440.00

Averages

612.47

High

700.00

Goldman Sachs

NULL -> Buy

maintain

$621 -> $714

2026-01-09

New

Reason

Goldman Sachs

Price Target

$621 -> $714

2026-01-09

New

maintain

NULL -> Buy

Reason

Goldman Sachs raised the firm's price target on Intuitive Surgical to $714 from $621 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.

Bernstein

Outperform

maintain

$700 -> $740

2026-01-09

New

Reason

Bernstein

Price Target

$700 -> $740

2026-01-09

New

maintain

Outperform

Reason

Bernstein raised the firm's price target on Intuitive Surgical to $740 from $700 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.

BTIG

Buy

maintain

$589 -> $616

2026-01-08

New

Reason

BTIG

Price Target

$589 -> $616

2026-01-08

New

maintain

Buy

Reason

BTIG raised the firm's price target on Intuitive Surgical to $616 from $589 and keeps a Buy rating on the shares. Analysis of the Dv5 launch suggests its value extends beyond higher system average selling prices, with the growing install base also driving incremental I&A revenue through increased utilization and new procedures, the analyst tells investors in a research note. Based on management commentary and Street assumptions, Dv5 is estimated to account for about 25% of modeled FY26 revenue growth and roughly 35% in FY27, with its impact better understood by examining contributions across both System and I&A revenue rather than topline alone, the firm says.

BTIG

Buy

maintain

$589 -> $616

2026-01-07

New

Reason

BTIG

Price Target

$589 -> $616

2026-01-07

New

maintain

Buy

Reason

BTIG raised the firm's price target on Intuitive Surgical to $616 from $589 and keeps a Buy rating on the shares. Analysis of the Dv5 launch suggests it accounts for roughly 25.3% of Street-modeled revenue growth in FY26 and 34.5% in FY27, the analyst tells investors in a research note. While this may appear low given the launch's strategic importance, a deeper look at its impact on both System and Instruments & Accessories revenue provides a fuller view of its contribution to overall growth, BTIG says.

Barclays

NULL -> Overweight

maintain

$635 -> $686

2026-01-07

New

Reason

Barclays

Price Target

$635 -> $686

2026-01-07

New

maintain

NULL -> Overweight

Reason

Barclays raised the firm's price target on Intuitive Surgical to $686 from $635 and keeps an Overweight rating on the shares. The firm cites an increased target multiple, which is in-line with the recent increase in comparable stocks, for the target bump.

Evercore ISI

In Line

maintain

$540 -> $580

2026-01-05

New

Reason

Evercore ISI

Price Target

$540 -> $580

2026-01-05

New

maintain

In Line

Reason

Evercore ISI raised the firm's price target on Intuitive Surgical to $580 from $540 and keeps an In Line rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.

Valuation Metrics

The current forward P/E ratio for Intuitive Surgical Inc (ISRG.O) is 60.51, compared to its 5-year average forward P/E of 57.17. For a more detailed relative valuation and DCF analysis to assess Intuitive Surgical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

57.17

Current PE

60.51

Overvalued PE

66.77

Undervalued PE

47.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

38.54

Current EV/EBITDA

42.27

Overvalued EV/EBITDA

45.55

Undervalued EV/EBITDA

31.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

16.43

Current PS

18.15

Overvalued PS

19.47

Undervalued PS

13.39

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress areBuying! The buying amount has increased837.5%over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ISRG News & Events

Events Timeline

No data

News

4.5

01-07Yahoo Finance

S&P 500 Hits New High as Amazon Stocks Flash Buy Signals

3.5

01-06Fool

Intuitive Surgical (ISRG) Sees 13% Increase in da Vinci Robot Demand, Receives FDA Approval

7.5

01-06NASDAQ.COM

Intuitive Surgical Increases da Vinci Robot Installations by 13% Year-Over-Year

People Also Watch

Frequently Asked Questions

What is Intuitive Surgical Inc (ISRG) stock price today?

The current price of ISRG is 584.51 USD — it has decreased -0.1 % in the last trading day.

What is Intuitive Surgical Inc (ISRG)'s business?

Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.

What is the price predicton of ISRG Stock?

What is Intuitive Surgical Inc (ISRG)'s revenue for the last quarter?

Intuitive Surgical Inc revenue for the last quarter amounts to 2.51B USD, increased 22.91 % YoY.

What is Intuitive Surgical Inc (ISRG)'s earnings per share (EPS) for the last quarter?

Intuitive Surgical Inc. EPS for the last quarter amounts to 1.95 USD, increased 25.00 % YoY.

What changes have occurred in the market's expectations for Intuitive Surgical Inc (ISRG)'s fundamentals?

How many employees does Intuitive Surgical Inc (ISRG). have?

Intuitive Surgical Inc (ISRG) has 15638 emplpoyees as of January 09 2026.

What is Intuitive Surgical Inc (ISRG) market cap?

Today ISRG has the market capitalization of 207.41B USD.